Second-line chemotherapy for recurrent non-small cell lung cancer: Do new agents make a difference?

Lung Cancer

Volumn 29, Issue 2, 2000, Pages 91-104

  Ferrigno, Domenico ^a   Buccheri, Gianfranco ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Chemotherapy; Non small cell lung cancer; Recurrent disease; Second line treatment

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; NAVELBINE; NEW DRUG; PACLITAXEL; TAXANE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUGS, INVESTIGATIONAL; HUMANS; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SALVAGE THERAPY; TAXOIDS; VINBLASTINE;

EID: 0033837509     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00112-4     Document Type: Article

References (92)

1. Ihde D.C. Chemotherapy of lung cancer. N. Engl. J. Med. 327:1992;1434-1441.
2. Squires T.S., Tong T. Cancer statistics. CA Cancer J. Clin. 43:1993;7-26.
3. Mountain C.F. Revisions in the international system for staging lung cancer. Chest. 111:1997;1710-1717.
4. Kayser K., Bulzebruck H., Probst G. et al. Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients. Cancer. 59:1987;355-361.
5. Rossing T.H., Rossing R.G. Survival in lung cancer: an analysis of the effects of age, sex, resectability, and histopathologic type. Am. Rev. Respir. Dis. 126:1982;771-777.
6. Martini N., Bains M.S., Burt M.E. et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J. Thorac. Cardiovasc. Surg. 109:1995;120-129.
7. Masters G.A., Vokes E.E. Should non-small cell carcinoma of the lung be treated with chemotherapy? pro: chemotherapy is for non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 151:1995;1285-1287.
8. Belani C.P. Multimodality management of regionally advanced non-small-cell lung cancer. Semin. Oncol. 20:1993;302-314.
9. Haskell C.M. Chemotherapy and survival of patients with non-small cell lung cancer: a contrary view. Chest. 99:1991;1325-1326.
10. Vokes E.E., Bitran J.D., Vogelzang N.J. Chemotherapy for non-small cell lung cancer: a continuing challenge. Chest. 99:1991;1326-1328.
11. Buccheri G. Chemotherapy and survival in non-small cell lung cancer: the old ’vexata questio’. Chest. 99:1991;1328-1329.
12. Douglas I.S., White S.R. Should non-small cell carcinoma of the lung be treated with chemotherapy? con: therapeutic empiricism - the case against chemotherapy in non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 151:1995;1288-1291.
13. Johnson D.H. Chemotherapy for metastatic non-small-cell lung cancer: can that dog hunt. J. Natl. Cancer Inst. 85:1993;766-767.
14. Coates A., Forbes J. Is chemotherapy for non-small cell lung cancer worthwhile? Lancet. 342:1993;344.
15. Smith I.E. Palliative chemotherapy for advanced non-small cell lung cancer. Br. Med. J. 308:1994;429-430.
16. Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough. J. Clin. Oncol. 11:1993;1866-1872.
17. Souquet P.J., Chauvin F., Boissel J.P. et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 342:1993;19-21.
18. Marino P., Pampallona S., Preatoni A. et al. Chemotherapy versus supportive care in advanced non-small-cell lung cancer: results of a meta-analysis of the literature. Chest. 106:1994;861-865.
19. Alberti W., Anderson G., Bartolucci A. et al. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. 311:1995;899-909.
20. Anderson H., Lund B., Bach F. et al. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 12:1994;1821-1826.
21. Ellis P.A., Smith I.E., Hardy J.R. et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br. J. Cancer. 71:1995;366-370.
22. Thongprasert S., Sanguanmitra P., Juthapan W. et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer. 24(1):1999;17-24.
23. Bunn P.A. The treatment of non-small cell lung cancer: current perspectives and controversies, future directions. Semin. Oncol. 21(suppl.6):1994;49-59.
24. Webb A., O’Brien M. Where to go with new expensive treatment in NSCLC. Br. J. Cancer. 78(2):1998;159-162.
25. Crino L., Clerici M., Figoli F. Chemotherapy of advanced non-small cell lung cancer: a comparison of three active regimes. Ann. Oncol. 6:1995;347-353.
26. Minna J.D., Pass H.I., Gladstein H. Cancer of the lung. De Vita V.T. Jr, Hellman S., Rosemberg S.A. Cancer: Principles and Practice of Oncology. 1989;591-705 Lippencott, Philadelphia, PA.
27. Johnson D.H. Chemotherapy for unresectable non-small cell lung cancer. Semin.Oncol. 17(suppl 7):1990;20-29.
28. Le Chevalier T., Brisgand D., Douillard J.-Y. et al. Randomized study of vinorelbine and cis-platin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small- cell lung cancer: results of a European Multicenter trial including 612 patients. J. Clin. Oncol. 12:1994;360-367.
29. Wozniak A.J., Crowley J.J., Balcerzak S.P. et al. Randomized trial comparing cisplatin with Cisplatin plus Vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study. J. Clin. Oncol. 16:1998;2459-2465.
30. Bonomi P.D., Kim K., Chang A. Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin G-CSF versus cisplatin in advanced non-small cell lung cancer: Eastern Cooperative Oncology Group. Proc. Am. Soc. Clin. Oncol. 15:1996;1145A.
31. Cardenal F., Paz Lopez-Cabrerizo M. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 17:1999;12-18.
32. Crino L., Conte P.F., De Marinis F. A randomized trial of gemcitabine cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC): a multi-centre phase III study. Proc. Am. Soc. Clin. Oncol. 17:1998;455A.
33. Comella P., Panza N., Frasci G. et al. Gemcitabine (GEM)-cisplatin (CDDP)-vinorelbine (VNR) combination in advanced non-small cell lung cancer (NSCLC). a phase II randomized study. Proc. Am. Soc. Clin. Oncol. 16:1997;449A.
34. Eastern Cooperative Oncology Group. A randomised phase III trial in metastatic non-small cell lung cancer. ECOG Meeting Agenda 1996. p. 482.
35. Pronzato P., Landucci M., Vaira F. Failure of vinorelbine to produce responses in pre-treated non-small cell lung cancer patients. Anticancer Res. 14:1994;1413-1416.
36. Rinaldi M., Della Giulia M., Venturo I. Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 13:1994;360A.
37. Santoro A., Maiorino L., Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer. 11(130):1994;1.
38. Barr F., Clinthorne H.M.D., Bendel S. et al. A phase II study of gemcitabine and vinorelbine salvage chemotherapy for taxane resistant non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;496A.
39. Gian V., Hainsworth J.D., Burris H.A. et al. Combination gemcitabine and vinorelbine in the second-line treatment of non-small cell lung cancer (NSCLC): a phase II study of the Minnie Pearl Cancer Research Network. Proc. Am. Soc. Clin. Oncol. 18:1999;505A.
40. Johnson D.H., Paul D.M., Hande K.R. et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: a phase II trial. J. Clin. Oncol. 14:1996;2054-2060.
41. Klastersky J., Sculier J.P. Cisplatin plus taxol in non-small cell lung cancer: a dose finding trial. Proc. Am. Soc. Clin. Oncol. 36:1995;1423A.
42. Pirker R., Krajnik G., Zochbauer S. Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. Oncol. 6:1995;833-835.
43. Belli L., Le Chevalier T., Gottfried M. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14:1995;1058A.
44. Belani C.P., Aisner J., Hiponia D. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin. Oncol. 22(suppl 9):1995;7-9.
45. Bunn P.A., Kelly K. A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Center study. Semin. Oncol. 22(suppl 9):1995;2-6.
46. Giaccone G., Huizing M., Postmus P.E. Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin. Oncol. 22(suppl 9):1995;78-82.
47. Langer C., Kaplan R., Rosvold E. Paclitaxel (P) by 1 hour (h) infusion combined with carboplatin (C) in advanced non-small cell lung carcinoma. Proc. Am. Soc. Clin. Oncol. 15:1996;A1200.
48. Murphy W.K., Winn R.J., Huber M. Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum-containing chemotharapy. Proc. Am. Soc. Clin. Oncol. 13:1999;363A.
49. Tan V., Herrera C., Einzig A.I. Taxol is active as a 3 or 24 hour infusion in non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 14:1995;366A.
50. Ruckdeschel J., Wagner H., Williams C. Second-line chemotherapy for resistant metastatic non-small cell lung cancer: the role of Taxol. Proc. Am. Soc. Clin. Oncol. 13:1994;357A.
51. Socinski M.A., Steagall A., Gillenwater H. Second-line chemotherapy with 96 hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. Cancer Invest. 17(3):1999;181-188.
52. Hainsworth J.D., Thompson D.S., Greco A. Paclitaxel by 1 h infusion: an active drug in metastatic non-small cell lung cancer. J. Clin. Oncol. 13:1995;1609-1614.
53. Roa V., Conner A., Mitchell R.B. Carboplatin and paclitaxel for previously treated patients with non-small cell lung cancer. Cancer Invest. 16(6):1998;381-384.
54. Chang A.Y., DeVore R.F., Johnson D. Pilot study of vinorelbine (Navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin. Oncol. 23(suppl 5):1996;19-21.
55. Stewart D.J., Tomiak E.M., Goss G. et al. Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer. 15:1996;115-123.
56. Georgoulias V., Kouroussis C., Kalolyris L. et al. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin. Oncol. 24(suppl 12):1997;S61-S66.
57. Rigas J.R., Pfister D.G., Miller V.A. Combination trials of edatrexate with paclitaxel or cisplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 11(suppl 1):1994;479.
58. Stathopoulos G.P., Rigatos S., Malamos N.A. Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol. Rep. 6(4):1999;797-800.
59. Fossella F.V., Lee J.S., Shin D.M. Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J. Clin. Oncol. 13:1995;645-651.
60. Burris H., Eckhardt J., Fields S. Phase II trials of taxotere in patients with non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 12:1993;35A.
61. Fossella F.V. Single-agent docetaxel in patients with refractory non-small cell lung cancer. Oncology. 7:1997;11-15.
62. Fossella F.V., Lee J.S., Berille J. Summary of phase II data of docetaxel (Taxotere), an active agent in the first-line and second-line treatment of advanced non-small cell lung cancer. Semin.Oncol. 22:1995;22-29.
63. Alexopoulos K., Kouroussis C., Androulakis N. et al. Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial. Cancer Chemother. Pharmacol. 43(3):1999;257-262.
64. Androulakis N., Papadakis E., Bania E. et al. Second line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II trial. Proc. Am. Soc. Clin. Oncol. 18:1999;494A.
65. Hotton K.M., Kim K., Larson M.L. et al. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. 18:1999;509A.
66. Shepherd F.A., Gralla R., Ramiau R. et al. Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Eur. J. Cancer. 35(suppl 4):1999;S247.
67. 2 versus vinorelbine/ifosfamide for non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy (PBC). Proc. Am. Soc. Clin. Oncol. 18:1999;460A.
68. Crino L., Mosconi A.M., Scagliotti G.V. et al. Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial. Semin. Oncol. 25(suppl 9):1998;23-26.
69. Rossi A., Perrone F., Barletta E. et al. Activity of gemcitabine (GEM) in cisplatin-pretreated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 trial. Proc. Am. Soc. Clin. Oncol. 18:1999;484A.
70. Baas P., Codrington H., Muller M. et al. Second line gemcitabine (G) therapy in non-small cell lung cancer (NSCLC) stage IIIb and IV. Proc. Am. Soc. Clin. Oncol. 18:1999;495A.
71. Reddy G.R., Gandara D.R., Edelman M.J. et al. Gemcitabine (GEM) in platinum (PLAT) treated non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;521A.
72. Androulakis N., Kouroussis C., Kakolyris S. et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann. Oncol. 9(10):1999;1127-1130.
73. Negoro S., Fukuoka M., Niitani H. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 co-operative study group. Jpn. J. Cancer Chemother. 18:1991;1013-1019., Gan to Kagaku Ryoho.
74. Nakai H, Fukuoka M, Furuse K. An early phase II study of CPT-11 for primary lung cancer. Jpn. J. Cancer Chemother. 18:1991;607-612.
75. Nakanishi Y., Takayama K., Takano K. et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am. J. Clin. Oncol. 22(4):1999;399-402.
76. Parker S.L., Tong T., Bolden S. Cancer statistics. CA Cancer J. Clin. 65:1996;5-27.
77. Ihde D, Minna J.D. Non-small cell lung cancer. I. Biology, diagnosis, and staging. Curr. Probl. Cancer. 15:1991;61-104.
78. Billingham L.J., Cullen M.H., Woods J. Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer (NSCLC): results of a randomized trial evaluating palliation and quality of life. Lung Cancer. 18(suppl 1):1997;9.
79. Rapp E., Pater J.L., Willan A. et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6:1988;633-641.
80. Jaakkimainen L., Goodwin P.J., Pater J. et al. Counting the cost of chemotherapy in a Nation Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J. Clin. Oncol. 8:1990;1301-1309.
81. Millward M.J., Zalcberg J., Bishop J.F. et al. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 15:1997;750-758.
82. Le Chevalier T., Belli L., Monnier A. Phase II study of docetaxel (Taxotere) and cisplatin in advanced non small cell lung cancer (NSCLC): an interim analysis. Proc. Am. Soc. Clin. Oncol. 14:1995;1059A.
83. Zalcberg J.R., Bishop J.F., Millward M.J. Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14:1995;1062A.
84. Cole J.T., Gralla R.J., Marques C.B. Phase I-II study of cisplatin and docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 14:1995;1087A.
85. Shepherd F.A. Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin. Oncol. 26(suppl 4):1999;3-11.
86. Buccheri G., Vola F., Ferrigno D. Aspects of quality of life in patients with lung cancer: a three observer evaluation study. Int. J. Oncol. 2:1993;537-544.
87. Slevin M.L., Stubbs L., Plant H.J. Attitudes to chemotherapy: comparing views of patients with cancer and those of doctors, nurses, and general public. Br. Med. J. 300:1990;1458-1460.
88. Faller H., Lang H., Schilling S. Emotional distress and hope in lung cancer patients, as perceived by patients, relatives, physicians, nurse and interviewers. Psycho. Oncol. 4:1995;21-31.
89. Gandara D.R., Vokes E., Green M. et al. Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): confirmation of prolonged survival. Lung Cancer. 18(suppl 1):1997;21.
90. Robinet G., Kleisbauer J.-P., Thomas P. et al. Phase II study of docetaxel (Taxotere) in first and second line NSCLC. Lung Cancer. 18(suppl 1):1997;42.
91. Nakamura Y., Kunitoh H., Aono H. et al. A phase II trial of low-dose docetaxel (DCT) 60 mg/m2 in platinum-pretreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 18:1999;518A.
92. Clinical practice guidelines for treatment of unresectable non-small-cell lung cancer. J. Clin. Oncol. 15(8):1998;2996-3018.